Form 4: Rapport Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on September 23, 2026.
Summary
- Open-market sale: disposed of 1,952 Common Stock at $39.05 ($76,230) on September 23, 2026; holds 457,025 after (Direct).
- Open-market sale: disposed of 215 Common Stock at $39.86 ($8,570) on September 23, 2026; holds 456,810 after (Direct).
- Open-market sale: disposed of 43 Common Stock at $41.05 ($1,765) on September 23, 2026; holds 456,767 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $86,565 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Abraham Ceesay — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Open-market sale | Common Stock | 1,952 | $39 | $76.2K | 457,025 |
| 2026-09-23 | Open-market sale | Common Stock | 215 | $40 | $8.6K | 456,810 |
| 2026-09-23 | Open-market sale | Common Stock | 43 | $41 | $1.8K | 456,767 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Open-market sale (1,952 shares) |
| 2026-09-23 | Open-market sale (215 shares) |
| 2026-09-23 | Open-market sale (43 shares) |
Keywords
insider transaction, Form 4, RAPP, Rapport Therapeutics, Inc., bearish, Abraham Ceesay
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.